Abstract
The introduction of drugs that inhibit the GP IIb/IIIa receptor represents one of the most important new developments in the field of cardiovascular pharmacotherapeutics of the past decade. Thrombocytopenia associated with a GP IIb/IIIa inhibitor can occur in up to 5% of patients and is associated with poor clinical outcomes. Monitoring of the platelet count early after administration of these drugs is recommended and further assessment of the platelet count should be performed with long-term oral administration. Confirmation of true thrombocytopenia and an investigation of other potential etiologies are crucial initial diagnostic steps that should be taken when a platelet count of <100,000/cm3 is encountered. In patients receiving concomitant heparin, identification of heparin-induced thrombocytopenia using an enzyme-linked immunosorbent assay to detect anti-heparin-PF4 antibodies is preferred. Treatment recommendations depend upon the severity of thrombocytopenia and presence of bleeding. In general, GP IIb/IIIa inhibitor therapy should be stopped; conventional critical care instituted; and platelet transfusions considered if the platelet count is <10,000/cm3, if there is severe bleeding, or if an emergency invasive procedure is required. Readministration of GP IIb/IIIa inhibitors may be associated with an increased risk of thrombocytopenia in selected circumstances, and caution is advised if the patient had previously experienced a significant decline in the platelet count or developed drug-induced antibodies following prior use. Future areas of research should target the mechanism(s) of thrombocytopenia, more accurate diagnostic methods, and the risk of thrombocytopenia when these drugs are combined with other antiplatelet and anticoagulant agents.
Similar content being viewed by others
References
Cannon CP. Platelet glycoprotein IIb/IIIa receptor inhibitors in the management of acute coronary syndromes and coronary interventions. In: Braunwald, ed. Heart Disease Updates. Heart disease. A Textbook of Cardiovascular Medicine. Philadelphia: W.B. Saunders, 1998:1–10.
Topol EJ, Byzova TV, Plow EF. Platelet GP IIb/IIIa blockers. Lancet 1999;353:271–231.
Giugliano RP, Hyatt RR Jr. Thrombocytopenia with GP IIb/IIIa inhibitors: A meta-analysis (abst). J Am Coll Cardiol 1998;31:185.
Harrington RA, Sane DC, Califf RM, et al. for the TAMI Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1994;23:891–898.
Bovill EG, Terrin ML, Stump DC, et al. for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med 1991;115: 256–265.
Berkowitz SD, Sane DC, Sigmon KN, et al. for the EPIC Study Group. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311–319.
Berkowitz SD, Sparapani RA, Califf RM, Cohen M. Occurrence and significance of thrombocytopenia in unstable angina and non-Q-wave infarction in the ESSENCE trial (abstr). Blood 1997;90:81.
Berkowitz SD, Granger CB, Thompson T, Kleiman NS, Topol EJ, Califf RM. Thrombocytopenia was associated with greater hemorrhage and higher mortality in GUSTO IIb trial (abstr). Thromb Haemost 1997;236:PS-962.
McClure MW, Berkowitz SD, Sparapani R, et al. for the PURSUIT Investigators. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. Circulation 1999;99:2892–2900.
Giugliano RP, Antman EM, McCabe CH, et al. Factors associated with major hemorrhage during reperfusion therapy in acute myocardial infarction: A TIMI 14 sub study (abstr). J Am Coll Cardiol 1999;33(Suppl. A):398.
Cines DB. Glycoprotein IIb/IIIa antagonists: Potential induction and detection of drug-dependent antiplatelet antibodies. Am Heart J 1998;135(Suppl.):S152–S159.
Brieger DB, Mak KH, Kottke-Marchant C, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31: 1449–1459.
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330–1335.
Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost 1995;73:21–28.
Giugliano RP. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors? J Thromb Thrombolys 1998;5:191–202.
Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy. Circulation 1997;95:809–813.
Raskob GE, George JN. Thrombotic complications of antithrombotic therapy: A paradox with implications for clinical practice. Ann Intern Med 1997;127:839–841.
Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804–812.
Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194–2197.
Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70:554–561.
Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50: 20–25.
Tcheng JE, Kereiakes DJ, Braden G, et al. Safety of abciximab retreatment final clinical report of the ReoPro Readministration Registry (R3). J Am Coll Cardiol 1999;33(Suppl. A):14–15.
Giugliano RP, McCabe CH, Frey M, et al. First report of an intravenous and oral GP IIb/IIIa inhibitor administered in patients--Results of TIMI 15B (abstr). Eur Heart J 1999;20 (Suppl.):376.
Bednar B, Cook J, Holahan MA, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999;94: 587–599.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Llevadot, J., Coulter, S.A. & Giugliano, R.P. A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated with Glycoprotein IIb/IIIa Receptor Inhibitors. J Thromb Thrombolysis 9, 175–180 (2000). https://doi.org/10.1023/A:1018779116791
Issue Date:
DOI: https://doi.org/10.1023/A:1018779116791